Edition:
United States

Amarantus Bioscience Holdings Inc (AMBS.PK)

AMBS.PK on OTC Markets Group

0.06USD
--
Change (% chg)

-- (--)
Prev Close
$0.06
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
427,962
52-wk High
$0.09
52-wk Low
$0.01

Latest Key Developments (Source: Significant Developments)

Amarantus Bioscience received orphan drug designation from the US FDA
Wednesday, 10 Feb 2016 07:45am EST 

Amarantus Biosciences Holdings inc:Says it has received orphan drug designation from the US FDA for Eltoprazine in the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID).Published positive results from a Phase 2 initial proof-of-concept clinical study in February of 2015 in the journal Brain.  Full Article

Amarantus BioScience Holdings, Inc submits Orphan Drug Designation Application to FDA for Eltoprazine in the Treatment of Levodopa-Induced Dyskinesia
Thursday, 22 Oct 2015 09:15am EDT 

Amarantus BioScience Holdings, Inc:Says has submitted a request to the US FDA for orphan drug designation (ODD) for eltoprazine in the treatment of levodopa-induced dyskinesia (PD-LID).  Full Article

Amarantus closes $5.5 million capital infusion through issuance of preferred stock and secured debt convertible
Thursday, 1 Oct 2015 07:32am EDT 

Amarantus BioScience Holdings, Inc:Completed issuance of $2.75 million of newly designated Series H convertible preferred stock in a registered direct offering.Issues $2.75 million in secured debt in a private placement for a total of $5.5 million to a single institutional investor.  Full Article

Amarantus BioScience Holdings Inc receives orphan drug designation from the U.S. Food and Drug Administration for MANF for the treatment of retinal artery occlusion
Monday, 14 Sep 2015 10:30am EDT 

Amarantus BioScience Holdings Inc:Says U.S. Food and Drug Administration has granted company's investigational drug mesencephalic-astrocyte-derived neurotrophic factor orphan drug designation for the treatment of retinal artery occlusion.Retinal artery occlusion is a blockage of the blood supply to the retina which causes severe and sudden loss of vision.  Full Article

Amarantus Bioscience Holdings Inc announces acquisition of Cutanogen Corporation - From 8k
Wednesday, 15 Jul 2015 07:00am EDT 

Amarantus Bioscience Holdings Inc:Says exercised its previously disclosed option to acquire Cutanogen Corporation.Says pursuant to a Share Purchase Agreement among the Company and Lonza Walkersville, Inc. dated July 14, the Company paid $4,000,000 to Lonza upon closing.  Full Article

Amarantus BioScience Holdings enters into CRO agreement with Chiltern International
Thursday, 21 May 2015 07:05am EDT 

Amarantus BioScience Holdings:Enters into a clinical trial agreement with Chiltern International (Chiltern), a leading global contract research organization (CRO), to manage the clinical research and monitoring program services for the Phase 2b study of eltoprazine in Parkinson's disease levodopa-induced dyskinesia (PD-LID).Also completed its clinical investigator meetings in both the United States and European Union and is on track to commence enrollment and dosing for the 60-patient international, multi-center PD-LID study in the second quarter of 2015.  Full Article

Amarantus BioScience Holdings Inc granted European Union orphan drug designation for MANF for treatment of retinitis pigmentosa
Wednesday, 29 Apr 2015 07:05am EDT 

Amarantus BioScience Holdings Inc:European Commission, acting on positive recommendation from European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has granted orphan drug status for MANF.MANF (mesencephalic-astrocyte-derived neurotrophic factor) is for treatment of retinitis pigmentosa (RP).RP refers to group of inherited diseases causing retinal degeneration often leading to blindness.Company previously said in Dec. of 2014 that it also received orphan drug designation for MANF for treatment of RP from U.S. Food and Drug Administration (FDA).  Full Article

Amarantus BioScience Holdings Inc closes $5 million preferred stock financing
Monday, 27 Apr 2015 07:05am EDT 

Amarantus BioScience Holdings Inc:Says closing of a $5 million investment from Discover Growth Fund, a privately held mutual fund focused on investing in high growth opportunities in publicly-held, small capitalization companies.In exchange for the investment, Amarantus issued a new class of preferred stock (the Series G Preferred), that is convertible into Amarantus common stock at a fixed price of $0.06 per share.The Company intends to use the proceeds from this financing to further the development and commercialization of its therapeutic drug candidates, neurology diagnostic products, and for general working capital purposes.  Full Article

More From Around the Web